ライフサイエンスコーパス: cardiac troponin

1 arker, whereas the secondary definition used cardiac troponin.

2 Nearly all patients will have an elevated cardiac troponin.

3 Blood concentrations of cardiac troponin above the 99(th) percentile are a key c

4 Cardiac troponin and B-type natriuretic peptide (BNP) co

5 I(R146G), and cTnI(R21C) were complexed into cardiac troponin and exchanged into rat ventricular myof

6 sessment algorithm based on high-sensitivity cardiac troponin and sampling at 0 and 1 hour.

7 re observed across ncRNA types compared with cardiac troponins and cMyBP-C (cardiac myosin-binding pr

8 Measures of serum cardiac troponins and natriuretic peptides have become e

9 ype natriuretic peptide and high-sensitivity cardiac troponin), and clinical history (prior stroke).

10 Elevated levels of cardiac troponin, and especially their relative changes

11 Elevated levels of cardiac troponins are associated with adverse clinical o

12 led trial, we implemented a high-sensitivity cardiac troponin assay and the recommendations of the Un

13 agnosed due to the increasing sensitivity of cardiac troponin assays and is associated with adverse s

14 Implementation of high-sensitivity cardiac troponin assays and the recommendations of the U

15 High-sensitivity cardiac troponin assays enable myocardial infarction to

16 The introduction of more sensitive cardiac troponin assays has led to increased recognition

17 The improvement in cardiac troponin assays, especially in conjunction with

18 rdial injury was defined as any elevation in cardiac troponin at the time of clinical presentation or

19 r specificity, determination of the level of cardiac troponins became a predominant indicator for MI.

20 genase (LDH) and creatine kinase (CK), which cardiac troponins being the main accepted biomarkers for

21 as used to determine incorporation of mutant cardiac troponin C ( approximately 21%) into the KI-TnC-

22 c cardiomyopathy-associated mutant D145E, in cardiac troponin C (cTnC) C-domain, causes generalised i

23 Cardiac troponin C (cTnC) is the regulatory protein that

24 ique 31-residue N-terminal region that binds cardiac troponin C (cTnC) to increase the calcium sensit

25 The Ca(2+) sensor of the sarcomere, cardiac troponin C (cTnC), plays an important role in re

26 .I4M substitution in the N-terminal helix of cardiac troponin C (cTnC).

27 ac thin-filament activation, the N-domain of cardiac troponin C (N-cTnC) binds to Ca(2+) and interact

28 Coincident S-nitrosylation of cardiac troponin C decreases myocardial sensitivity to C

29 ation, in general, and for phospholamban and cardiac troponin C S-nitrosylation, in particular, in be

30 The ability of calcium-bound human cardiac troponin C to neutralize the inhibition of K206I

31 nt distance from the calcium binding site in cardiac troponin C, and do not affect either the binding

32 ndling proteins, including phospholamban and cardiac troponin C, thereby playing an essential and pre

33 tivity in the absence of calcium-bound human cardiac troponin C.

34 Measurement of the cardiac troponins, cardiac troponin T and cardiac tropon

35 ation of PKCepsilon expressing platelets and cardiac troponin clearly discriminates patients with 100

36 main of the troponin I subunit (TnIC) of the cardiac troponin complex.

37 Troponin-I (cTnI) is one of the subunits of cardiac troponin complexes and a pivotal biochemical mar

38 A cardiac troponin concentration of less than 5 ng/L ident

39 of this study was to assess associations of cardiac troponin concentration with cardiovascular disea

40 September 2016, reporting on associations of cardiac troponin concentration with first-ever CVD outco

41 In the general population, high cardiac troponin concentration within the normal range i

42 Cardiac troponin concentrations are used to identify pat

43 Variations in cardiac troponin concentrations by age, sex and time bet

44 patients with renal impairment and elevated cardiac troponin concentrations had a 2-fold greater ris

45 S pathway incorporating low high-sensitivity cardiac troponin concentrations rules out myocardial inf

46 thway with a pathway that incorporates lower cardiac troponin concentrations to risk stratify patient

47 tations on the structure and kinetics of the cardiac troponin core domain associated with the Ca(2+)-

48 n of muscle-enriched miRNAs with cMyBP-C and cardiac troponins could open a new path of integrating c

49 The introduction of high-sensitivity cardiac troponin (cTn) assays has improved sensitivity f

50 It is unknown whether more sensitive cardiac troponin (cTn) assays maintain their clinical ut

51 institutions transitioning from conventional cardiac troponin (cTn) assays.

52 Cardiac troponin (cTn) elevation is a common finding in

53 Cardiac troponin (cTn) is a key molecule in the regulati

54 Measures of cardiac troponin (cTn) may have lower specificity for my

55 ropriate clinical decision values (CDVs) for cardiac troponin (cTn) owing to limitations in the curre

56 hain (MHC)-beta to MHC-alpha and upregulated cardiac troponin (cTn)-T and tropomyosin, as well as cTn

57 estricted protein that is more abundant than cardiac troponins (cTn) and is released more rapidly aft

58 schemic stroke (AIS) have elevated levels of cardiac troponins (cTn).

59 Cardiac troponins (cTns) are the cornerstone of diagnosi

60 Cardiac troponin detected by new-generation, highly sens

61 IV histone infusion caused time-dependent cardiac troponin elevation to indicate cardiac injury.

62 High-sensitivity-cardiac troponin for accelerated diagnosis of acute myoc

63 rest in widening the use of high-sensitivity cardiac troponins for population cardiovascular disease

64 Circulating cardiac troponin has been associated with adverse progno

65 The structured use of serial cardiac troponin has the potential to facilitate risk st

66 Low values of high-sensitivity cardiac troponin (hs-cTn) and coronary artery calcium (C

67 High-sensitivity cardiac troponin (hs-cTn) assays have been used clinical

68 Until now, high-sensitivity cardiac troponin (hs-cTn) assays were mainly developed f

69 Using high-sensitivity cardiac troponin (hs-cTn) assays with sex-specific 99th

70 nal proBNP (NT-proBNP), and high-sensitivity cardiac troponin (hs-cTn) concentrations for diagnosis a

71 myocardial infarction using high-sensitivity cardiac troponin (hs-cTn) concentrations irrespective of

72 High-sensitivity cardiac troponin (hs-cTn) I or T methods have been in us

73 on the association between high-sensitivity cardiac troponin (hs-cTn) levels and outcomes in patient

74 Society of Cardiology (ESC) high-sensitivity cardiac troponin (hs-cTn) measurement at presentation an

75 wledge the emerging role of high-sensitivity cardiac troponin (hs-cTnl) for risk stratification and t

76 a modified HEART score </=3 (which includes cardiac troponin I <0.04 ng/mL at 0 and 3 hours) were ra

77 fabricated with an immobilized antibody for cardiac troponin I (anti-cTnI) on a photoresponsive comp

78 dots (afGQDs) conjugated with antibody anti-cardiac Troponin I (anti-cTnI) to detect cardiac marker

79 most specific markers for cardiac injury are cardiac troponin I (cTnI) and cardiac troponin T (cTnT)

80 ing in PKA-site dependent phosphorylation of cardiac troponin I (cTnI) and phospholamban (PLN).

81 Practice guidelines regard cTnT and cardiac troponin I (cTnI) as equally sensitive and speci

82 formance metrics of a novel high-sensitivity cardiac troponin I (cTnI) assay for this purpose.

83 Cardiac troponin I (cTnI) geometric mean decreased by 34

84 ifically monophosphorylates Ser(23) of human cardiac troponin I (cTnI) in isolation and in the trimer

85 During beta-adrenergic stimulation, cardiac troponin I (cTnI) is phosphorylated by protein k

86 Both tobacco smoking and circulating cardiac troponin I (cTnI) levels are associated with the

87 Two hypertrophic cardiomyopathy-associated cardiac troponin I (cTnI) mutations, R146G and R21C, are

88 t proteins revealed site-specific changes in cardiac Troponin I (cTnI) phosphorylation, as well as a

89 , which coincided with a similar increase in cardiac troponin I (cTnI) protein, the established marke

90 The cardiac troponin I (cTnI) R145W mutation is associated w

91 ition, a competitive binding assay to detect cardiac Troponin I (cTnI) was used as an example to demo

92 highly sensitive and label-free detection of cardiac troponin I (cTnI), a biomarker for diagnosis of

93 the enrichment and comprehensive analysis of cardiac troponin I (cTnI), a gold-standard cardiac bioma

94 pro b-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), and fibrinogen- were rapidly

95 PKA targets the N-terminus (Ser-23/24) of cardiac troponin I (cTnI), cardiac myosin-binding protei

96 osed for the ultrasensitive immunosensing of Cardiac Troponin I (cTnI).

97 quantities of monoclonal antibodies against cardiac troponin I (cTnI).

98 Drug Administration-cleared high-sensitivity cardiac troponin I (hs-cTnI) assays.

99 myocardial infarction using high-sensitivity cardiac troponin I (hs-cTnI) have been identified.

100 c troponin T (hs-cTnT), and high-sensitivity cardiac troponin I (hs-cTnI) were determined in plasma s

101 Quartiles of BNP and high-sensitivity cardiac troponin I (hs-cTnI) were included in adjusted m

102 ed at baseline and 8 weeks: high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-type natr

103 tionship between changes in high-sensitivity cardiac troponin I (hsTnI) and cardiovascular outcomes.

104 We measured high-sensitivity cardiac troponin I (hsTnI) in 12 956 and BNP in 11 076 p

105 e molecular mechanism(s) of the mutant human cardiac troponin I (K206I), we tested the Ca(2+) depende

106 with mice expressing a pseudophosphorylated cardiac troponin I (S23D and S24D; TnI-PP).

107 Autoimmune response to cardiac troponin I (TnI) induces inflammation and fibros

108 e is a progressive increase in expression of cardiac troponin I (TnI), with a concurrent decrease in

109 KEY POINTS: Mutations in genes encoding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2

110 Cardiac troponin I (TNNI3) gene mutations account for 3%

111 : the sarcomeric mutations in genes encoding cardiac troponin I (TNNI3p.98truncation ) and cardiac tr

112 ors showed extraordinary sensitivity towards cardiac troponin I [1.7microA/(ng/mL) in phosphate buffe

113 rary primary prevention population, baseline cardiac troponin I and BNP were associated with the risk

114 n of CMBK resulted in higher serum levels of cardiac troponin I and elevated amounts of reactive oxyg

115 he measurement of the heart attack indicator cardiac troponin I and is shown to successfully combine

116 ncreased expression of the maturation marker cardiac troponin I and significantly increased action po

117 vels of B-type natriuretic peptide (BNP) and cardiac troponin I are associated with adverse outcomes

118 he impact of implementing a high-sensitivity cardiac troponin I assay with sex-specific diagnostic th

119 Use of the high-sensitivity cardiac troponin I assay with sex-specific thresholds in

120 ons at presentation using a high-sensitivity cardiac troponin I assay.

121 roperties and still enabled the detection of cardiac troponin I at pg/mL concentrations in 10% serum

122 us biomolecular recognition of model analyte cardiac troponin I by two antibody fragments brought the

123 rdial injury was defined as high-sensitivity cardiac troponin I concentration >99th centile of 16 ng/

124 acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L ide

125 Plasma cardiac troponin I concentration was measured with a hig

126 e myocardial injury (high-sensitivity plasma cardiac troponin I concentration, 4.3 ng/L [interquartil

127 y, as assessed by serial measurements of the cardiac troponin I concentration.

128 consecutive patients (n=2122) with elevated cardiac troponin I concentrations (>/=0.05 microg/L) at

129 ocardial ischemia, and an increase in plasma cardiac troponin I concentrations (1.4 [0.8-2.5] versus

130 We measured cardiac troponin I concentrations in 725 participants (6

131 ospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspe

132 Cardiac troponin I concentrations were less than 5 ng/L

133 rating age, sex, and paired high-sensitivity cardiac troponin I concentrations, was trained on 3,013

134 Low concentrations of high-sensitivity cardiac troponin I determined on presentation to the eme

135 vely enrolled and serial echocardiograms and cardiac troponin I evaluations were performed.

136 terferences when electrochemically detecting cardiac troponin I in complex biological samples.

137 valuated the performance of high-sensitivity cardiac troponin I in those with and without renal impai

138 Cardiac troponin I levels were normal in all patients, w

139 lic groups used to immobilise antibodies for cardiac troponin I marker.

140 syndrome (n=1218) underwent high-sensitivity cardiac troponin I measurement at presentation and 3 and

141 rds measured in transgenic mice expressing a cardiac troponin I mutation (R145G).

142 el we previously identified that HCM causing cardiac troponin I mutation Gly203Ser (cTnI-G203S) is as

143 We additionally measured human cardiac troponin I protein in 9 human plasma samples, an

144 Periprocedural cardiac troponin I significantly increased (F=3.64; P=0.

145 r the interaction between the Ca(2+) ion and cardiac troponin I subunit.

146 High-sensitivity cardiac troponin I testing is widely used to evaluate pa

147 f peptides afforded higher sensitivities for cardiac troponin I than those prepared by the chemisorpt

148 To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation a

149 high sensitivity assay for the detection of cardiac troponin I using electrical double layer gated h

150 4 (307-1312) ng/L, hs-cTnI (high sensitivity cardiac troponin I) 6.3 (3.4-13.0) ng/L, hs-CRP (high se

151 croarray analysis of serum biomarkers (e.g., cardiac troponin I) afforded up to 130-fold enhancement

152 199 (equivalent to Ser200 in mouse) of cTnI (cardiac troponin I) is significantly hyperphosphorylated

153 .59 (95% CI, 1.76-3.83) for high-sensitivity cardiac troponin I, 1.65 (95% CI, 1.12-2.44) for NT-proB

154 The device can detect serum cardiac troponin I, a biomarker of cardiac disease to 10

155 implified Pulmonary Embolism Severity Index, cardiac troponin I, brain natriuretic peptide, and lower

156 ompe disease, the relationship between cTnT, cardiac troponin I, creatine kinase (CK), CK-myocardial

157 s: Risk score and clinical outcomes based on cardiac troponin I, N-terminal pro-B-type natriuretic pe

158 Cardiac troponin I, N-terminal pro-B-type natriuretic pe

159 oprotein cholesterol ratio, high-sensitivity cardiac troponin I, NT-proBNP (N-terminal pro-B-type nat

160 system has been applied to the detection of cardiac Troponin I, the gold standard biomarker for the

161 he cardiac troponins, cardiac troponin T and cardiac troponin I, using sensitive methods, defines a t

162 A series of cardiac troponin I-interacting kinase (TNNI3K) inhibitor

163 High-sensitivity assays can quantify cardiac troponins I and T (hs-cTnI, hs-cTnT) in individu

164 oped for rapid and simultaneous screening of cardiac Troponin-I (cTnI) and cardiac-Troponin-T (cTnT)

165 The cardiac Troponin-I (cTnI) is one of the subunits of card

166 injury, and markedly reduced elaboration of cardiac troponin-I in coronary effluent during ESHP.

167 RNA signatures correlated with elevations in cardiac Troponin-I in severely injured hearts during EVH

168 gens, like cardiac myosin heavy chain-alpha, cardiac troponin-I, and adenine nucleotide translocator

169 of the clinical biomarker of cardiac injury, cardiac troponin-I, by 52+/-17% (P=1.01x10(-2)).

170 ed acute coronary syndrome, high-sensitivity cardiac troponin identified fewer patients with renal im

171 natriuretic peptide, ferritin, D-dimers, and cardiac troponin in addition to high C-reactive protein

172 i-square = 146; p < 0.001), and after adding cardiac troponins in women (DeltaC-statistic = 0.003; li

173 of a large proportion of patients with minor cardiac troponin increases (14 to 49 ng/l), the majority

174 Increases in cardiac troponin indicative of myocardial injury are com

175 The basal phosphorylation of cardiac troponin inhibitor (cTnI) and the myosin-binding

176 Cardiac troponin is an independent predictor of cardiova

177 Cardiac troponin is the preferred biomarker for diagnosi

178 ed mice at 24 hours, Ppara mice had elevated cardiac troponin levels compared with wild-type mice.

179 ial infarction and elevated high-sensitivity cardiac troponin levels often routinely undergo invasive

180 Circulating histones and cardiac troponin levels were obtained from serial blood

181 t size), a Biomarker Core (to measure plasma cardiac troponin levels), and a Data Coordinating Center

182 ble physiological effects (without affecting cardiac troponin levels), but short-term treatment did n

183 morphometry, neutrophil accumulation, blood cardiac troponin levels, and echocardiography and observ

184 rkers, for example, natriuretic peptides and cardiac troponin, may assist in the diagnosis of left ve

185 e sought to examine the relationship between cardiac troponins, natriuretic peptides, ECV and their a

186 ng, and cardiac biomarkers (high-sensitivity cardiac troponins, NT-proBNP [N-terminal pro-B-type natr

187 nal function, and the blood concentration of cardiac troponin often increases with declining glomerul

188 measurements included natriuretic peptides, cardiac troponins, plasminogen activator inhibitor-1, D-

189 IMI risk scores, which incorporate the first cardiac troponin, provided more diagnostic information.

190 Minimally elevated serum cardiac troponin reflects myocardial injury and is assoc

191 and altered stoichiometry between the three cardiac troponin subunits.

192 , who experienced an event associated with a cardiac troponin T >99th percentile of a normal referenc

193 A total of 5460 patients had at least one cardiac troponin T >=0.01 ng/mL; 1365 of these patients

194 chronic myocardial injury (high-sensitivity cardiac troponin T >=6 ng/L] and stress (N-terminal pro-

195 -specific acute cardiac stress (by measuring cardiac troponin T (cTnT) and N-terminal prohormone of b

196 However, it is not clear whether cardiac troponin T (cTnT) and troponin I (cTnI) are equi

197 erified assumption that chronically elevated cardiac troponin T (cTnT) levels fluctuate randomly arou

198 Elevated plasma cardiac troponin T (cTnT) levels in patients with neurom

199 The hypertrophic cardiomyopathy-causing cardiac troponin T (cTnT) mutation Delta160Glu (Delta160

200 embled on a screen-printed electrode for the cardiac troponin T (cTnT) was developed.

201 esent study was to evaluate whether elevated cardiac troponin T (cTnT) was independently associated w

202 iac injury are cardiac troponin I (cTnI) and cardiac troponin T (cTnT) which have been considered as

203 isopropylacrylamide (PNIPAAm) functionalised cardiac troponin T (cTnT) with anti-cTnT.

204 splicing of TNNT2, the gene that encodes for cardiac troponin T (cTnT), a biomarker of myocardial inj

205 tic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (cTnT), and genetic analysis.

206 Cardiac troponin T (cTnT), even at low concentrations, i

207 For the first time, we show that cardiac troponin T (cTnT), in part through its intrinsic

208 globin (MYG), bovine serum albumin (BSA) and cardiac troponin T (cTnT), respectively.

209 er Nkx2.5, or that of the myocardial marker, cardiac troponin T (cTnT).

210 rdial infarction, especially with the use of cardiac troponin T (cTnT).

211 tiation factor-15 (GDF-15), high-sensitivity cardiac troponin T (cTnT-hs) and haemoglobin, age, and p

212 anterior circulation and a high-sensitivity cardiac troponin T (hs-cTnT) acquired on the day of admi

213 High-sensitivity cardiac troponin T (hs-cTnT) and N-terminal B-type natri

214 Although small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with inciden

215 High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes used to rapid

216 tional level, with elevated high-sensitivity cardiac troponin T (hs-cTnT) concentrations (>/=14 ng/L)

217 tic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations were measure

218 rognostic value of baseline high-sensitivity cardiac troponin T (hs-cTnT) elevation in SCAD patients

219 implications of introducing high-sensitivity cardiac troponin T (hs-cTnT) into clinical practice and

220 High-sensitivity cardiac troponin T (hs-cTnT) is a biomarker of cardiovas

221 f an undetectable (<5 ng/l) high-sensitivity cardiac troponin T (hs-cTnT) level and an electrocardiog

222 hesized that any detectable high-sensitivity cardiac troponin T (hs-cTnT) level is associated with ad

223 s are preferable when using high-sensitivity cardiac troponin T (hs-cTnT) levels in the diagnosis of

224 Their high-sensitivity cardiac troponin T (hs-cTnT) levels were measured.

225 econdary endpoints included high-sensitivity cardiac troponin T (hs-cTnT) on day 4, left ventricular

226 CVD) but elevated levels of high-sensitivity cardiac troponin T (hs-cTnT) or N-terminal pro-B-type na

227 oninferiority of a 0/1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol in comparison with

228 ge, as assessed by elevated high-sensitivity cardiac troponin T (hs-cTnT) test results.

229 A 1-h algorithm based on high-sensitivity cardiac troponin T (hs-cTnT) testing at presentation and

230 Thus, we assessed whether high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical my

231 B-type natriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardi

232 uretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotei

233 ge, as assessed by elevated high-sensitivity cardiac Troponin T (hs-cTnT).

234 enes encoding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2) caused altered troponin prote

235 RNAs including the Insulin Receptor (Insr), Cardiac Troponin T (Tnnt2), Lim Domain Binding 3 (Ldb3)

236 ardiac troponin I (TNNI3p.98truncation ) and cardiac troponin T (TNNT2p.K217deletion ; also known as

237 The C-terminal region of cardiac troponin T (TnT), a tropomyosin-associated prote

238 are mutations in the TNNT2 gene that encodes cardiac troponin T (TnT).

239 Adding high-sensitive cardiac troponin T absolute change to the Revised Cardia

240 protein expression of cardiomyogenic markers cardiac troponin T and alpha-smooth muscle actin in CPCe

241 Measurement of the cardiac troponins, cardiac troponin T and cardiac troponin I, using sensiti

242 f muscle-enriched miRNAs with high-sensitive cardiac troponin T and cMyBP-C returned the highest area

243 High-sensitivity cardiac troponin T and creatine kinase-myocardial band w

244 of these transcripts paralleled the rise in cardiac troponin T and decayed at 30 days.

245 ype natriuretic peptide and high-sensitivity cardiac troponin T are frequently elevated in severe sep

246 per reference limit for the high-sensitivity cardiac troponin T assay (hs-cTnT) in 3 large independen

247 We measured the cardiac troponin T concentration at baseline with a high

248 The cardiac troponin T concentration was an independent pred

249 terminal pro-B-type natriuretic peptide, and cardiac troponin T concentrations in multivariate analys

250 type natriuretic peptide or high-sensitivity cardiac troponin T concentrations were independently ass

251 e ESC 0/1-h algorithm using high-sensitivity cardiac troponin T embedded in routine clinical care and

252 n 97.4% of the patients and high-sensitivity cardiac troponin T in 84.5%, with higher concentrations

253 sing serial measurements of high-sensitivity cardiac troponin T in clinical routine.

254 was defined as an absolute high-sensitivity cardiac troponin T increase of >/=14 ng/L from preoperat

255 acute chest pain, elevated high-sensitivity cardiac troponin T levels (>14 ng/l), and inconclusive e

256 Serum high-sensitivity cardiac troponin T levels and electrocardiograms were ob

257 However, changes in cardiac troponin T levels during the infusion did not di

258 In patients with NSTE-ACS and elevated cardiac troponin T levels, an early invasive strategy ha

259 ive and 24-hour postoperative high-sensitive cardiac troponin T measurements and the respective chang

260 ac investigations including high-sensitivity cardiac troponin T measurements at later time points or

261 Pre- and postoperative high-sensitive cardiac troponin T measurements demonstrated a majority

262 sus without either elevated high-sensitivity cardiac troponin T or NT-proBNP had a 10-year CV inciden

263 Elevations in high-sensitivity cardiac troponin T or NT-proBNP identify individuals wit

264 ociation rates in fully reconstituted WT and cardiac troponin T R92L and R92W thin filaments.

265 s, we used 2 mouse models of sarcomeric HCM (cardiac troponin T R92L and R92W) with differential myoc

266 nhanced myocardial damage evidenced by serum cardiac troponin T release in the rat and mouse cardiac

267 ype natriuretic peptide and high-sensitivity cardiac troponin T were measured 1, 2, and 7 days after

268 We measured cardiac troponin T with a highly sensitive assay (hs-cTn

269 hich most patients would have had a negative cardiac troponin T with older assays); and Group 4, thos

270 rmined pre- and postoperative high-sensitive cardiac troponin T with the occurrence of major adverse

271 144 patients with elevated high-sensitivity cardiac troponin T, 31 had signs of MI and 113 did not.

272 B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive prot

273 B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive prot

274 e protein, procalcitonin, ferritin, D-dimer, cardiac troponin T, and N-terminal pro-B-type natriureti

275 For a third trait, cardiac troponin T, investigation of regulatory domains

276 coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T.

277 1,200 patients with NSTE-ACS and an elevated cardiac troponin T.

278 e populations as determined by expression of cardiac troponin T.

279 gy in patients with NSTE-ACS and an elevated cardiac troponin T.

280 -day mortality, better than high-sensitivity cardiac troponin T.

281 women; 21.5% with elevated high-sensitivity cardiac troponin T; 17.7% with elevated NT-proBNP) with

282 ro-brain natriuretic peptide (NT-proBNP) and cardiac troponins T and I (TnT and TnI) for prognosticat

283 nano-gap device provides the capability for cardiac-troponin T (cTnT) measurements with co-existed 1

284 Cardiac Troponins (T and I) are well established protein

285 AT), matrix metalloproteinase-9 (MMP-9), and cardiac Troponin-T (cTnT) were evaluated by appropriate

286 through the detection and quantification of cardiac Troponin-T (cTnT).

287 rdial Infarction) evaluated high-sensitivity cardiac troponin-T (hs-cTnT) in a 1-hour acute myocardia

288 th myocardial damage (using high-sensitivity cardiac troponin-T [hs-cTnT]) and with coronary heart di

289 ificantly more cardiomyocytes, determined by cardiac troponin-T staining, in the MI zone of the QHG21

290 Left ventricular structure and function and cardiac troponin-T were among the top predictors for inc

291 normal biomarkers (hs-cTnT (high sensitivity cardiac troponin-T) <6 ng/L and NT-proBNP (N-terminal pr

292 tions between or near residues 112 to 136 of cardiac troponin-T, the crucial TnT1 (N-terminal domain

293 s screening of cardiac Troponin-I (cTnI) and cardiac-Troponin-T (cTnT) in a point-of-care sensor form

294 (RV) dysfunction on imaging, and a positive cardiac troponin test result.

295 rdial Infarction recommends high-sensitivity cardiac troponin testing and classification of patients

296 High-sensitivity cardiac troponin testing may improve the risk stratifica

297 ectrochemical sensor platform for monitoring cardiac troponins through the detection and quantificati

298 Cardiac troponin was detectable in 80.0% (hs-cTnI: 82.6%

299 Cardiac troponins were normal, whereas N-terminal pro B-

300 , and a vast majority of children had raised cardiac troponin when checked.